Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Carmat: Edison Open House Healthcare 2022

Carmat: Edison Open House Healthcare 2022

Carmat — 4 videos in collection

More on this equity

Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. It received a CE mark in the EU and Carmat is conducting an early feasibility study in the United States.

• Tell us about Carmat’s history and vision.
• Please explain how physiological heart replacement therapy differs from other artificial hearts.
• How large do you anticipate the unmet need in the bridge-to-transplant market to be?
• Please explain what’s been happening for Carmat in 2021, including its first commercial implants.
• What are the next steps in terms of commercial implant trials in Europe and the United States?
• When do you expect to receive approvals, particularly in the US market?
• Which milestones should investors focus on in the coming year?

< Previous
Next >

You may also be interested in these:

Healthcare

Carmat - Edison Open House interview

Healthcare

Carmat - executive interview with Stéphane Piat

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free